STAT3 and myelodysplastic syndrome: AZD9150, without any delivery agent, was shown to inhibit STAT3 expression in primary AML/MDS leukemia stem cells and to inhibit leukemic cell growth in vitro and in vivo using PDX models of AML/MDS [347].